Inside Passage

cells surrounding nasal cavities in indigo with glowing yellow around the edges

The Irvine Lab is developing an intranasal vaccine that can bypass multiple barriers in the nasal cavity and activate a frontline defense against mucosally-transmitted pathogens. Such immunization strategies are much needed across the infectious disease landscape but are limited by poor uptake across mucosal surfaces. In a cover story appearing in Science Translational Medicine, the researchers describe how they use the naturally-occurring protein albumin to chaperone vaccine components across the mucosal lining and into the nasal-associated lymphoid tissues where they can generate an effective immune response. The work is also featured in the 2022 Image Awards exhibition.